Dana Singer, MD, Medical Director, is a Safety Physician at Jazz Pharmaceuticals. Trained as a pediatrician at the Dana-Dwek Children’s Hospital in Tel Aviv, Dr. Singer brings over a decade of combined clinical and pharmaceutical industry experience, including leadership in pharmacovigilance and benefit-risk assessment. At Jazz, she leads safety activities for products in the neuroscience and sleep medicine spaces, guiding signal evaluation, risk management planning, and cross-functional safety reviews. Dr. Singer leads cross-functional safety teams and partners with global stakeholders to advance a patient-centered safety culture. She recently played a central role in developing real-world evidence strategies that support internal decision-making and informed benefit-risk discussions for marketed products. Bringing a global perspective to rebuilding safety around the patient, Dr. Singer aspires to enhance bedside clinical care with innovative drug safety practices.
In an era of increasing complexity in drug development and real-world use, patient safety must be re-centered as a multidisciplinary, patient-facing function - not just a regulatory requirement. This panel, Rebuilding Safety Around the Patient: Moving Medical Safety Beyond the Silo and Back to the Bedside, explores how safety science can evolve beyond traditional silos to actively engage with patients, clinicians, and data at the point of care. Panelists will share practical strategies for bridging the gap between pharmacovigilance and patient experience through cross-functional collaboration, patient-reported outcomes, and ethical transparency. Join us for a thought-provoking discussion on reimagining medical safety as a bedside ally rather than a back-office function.